Yarrow Bioscience (YARW) Total Current Liabilities (2016 - 2026)

Yarrow Bioscience (YARW) has reported Total Current Liabilities for 11 consecutive years, with $1.5 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Total Current Liabilities fell 73.58% year-over-year to $1.5 million; the trailing twelve-month figure through Jun 2026 stood at $1.5 million (down 73.58% YoY), and the FY2025 full-year result was $2.4 million, down 83.84% from the prior year.
• Total Current Liabilities rose to $1.5 million in Q2 2026 per YARW's latest filing, from $1.2 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $14.8 million in Q4 2024 and bottomed at $1.2 million in Q1 2026.
• Historically, Total Current Liabilities has averaged $7.6 million across 5 years, with a median of $7.2 million in 2023.
• The sharpest annual moves came in 2024 and 2026: Total Current Liabilities soared 96.59% in 2024, then plunged 89.94% in 2026.
• Over 5 years, Total Current Liabilities stood at $9.3 million in 2022, then retreated by 19.34% to $7.5 million in 2023, then jumped by 96.59% to $14.8 million in 2024, then tumbled by 83.84% to $2.4 million in 2025, then plunged by 35.62% to $1.5 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $1.5 million, $1.2 million, and $2.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.